| Arthritis, Psoriatic
Otezla vs Sotyktu
Side-by-side clinical, coverage, and cost comparison for arthritis, psoriatic.Deep comparison between: Otezla vs Sotyktu with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsSotyktu has a higher rate of injection site reactions vs Otezla based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Sotyktu but not Otezla, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Otezla
Sotyktu
At A Glance
Oral
Once or twice daily
PDE4 inhibitor
Oral
Daily
TYK2 inhibitor
Indications
- Arthritis, Psoriatic
- Psoriasis vulgaris
- Behcet Syndrome
- Psoriasis vulgaris
- Arthritis, Psoriatic
Dosing
Arthritis, Psoriatic, Psoriasis vulgaris, Behcet Syndrome Adults: OTEZLA 30 mg twice daily or OTEZLA XR 75 mg once daily orally after 5-day titration starting at 10 mg; reduce to 30 mg once daily in severe renal impairment (OTEZLA XR not recommended in severe renal impairment).
Arthritis, Psoriatic, Psoriasis vulgaris (pediatric >=6 years) Weighing >=50 kg: OTEZLA 30 mg twice daily or OTEZLA XR 75 mg once daily orally after weight-based titration; weighing 20 to <50 kg: OTEZLA 20 mg twice daily orally; reduce to once daily dosing in severe renal impairment.
Psoriasis vulgaris, Arthritis, Psoriatic 6 mg orally once daily, with or without food; do not crush, cut, or chew tablets; not recommended in severe hepatic impairment (Child-Pugh C).
Contraindications
- Known hypersensitivity to apremilast or to any of the excipients in the formulation
- History of hypersensitivity reaction to deucravacitinib or any excipient in SOTYKTU
Adverse Reactions
Most common (>=2%) Diarrhea, nausea, headache, upper respiratory tract infection, vomiting, abdominal pain upper, nasopharyngitis
Serious Hypersensitivity, depression, weight decrease, severe worsening of psoriasis (rebound)
Most common (>=1%) Upper respiratory infections, blood creatine phosphokinase increased, herpes simplex, mouth ulcers, folliculitis, acne
Serious Pneumonia, COVID-19, malignancies including breast cancer, hepatocellular carcinoma, and lymphoma
Pharmacology
Apremilast is an oral small molecule inhibitor of phosphodiesterase 4 (PDE4) specific for cyclic adenosine monophosphate (cAMP); PDE4 inhibition increases intracellular cAMP levels and reduces pro-inflammatory cytokines including IL-17, IL-22, and TNF-alpha in blood and skin.
TYK2 inhibitor; deucravacitinib binds the regulatory domain of TYK2, allosterically inhibiting receptor-mediated TYK2 activation and downstream STAT signaling via the JAK-STAT pathway.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Otezla
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (12/12) · Qty limit (9/12)
Sotyktu
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (9/12)
UnitedHealthcare
Otezla
- Covered on 4 commercial plans
- PA (8/8) · Step Therapy (2/8) · Qty limit (8/8)
Sotyktu
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (6/8) · Qty limit (6/8)
Humana
Otezla
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Sotyktu
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAmgen Safety Net Foundation: Otezla
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableAssistance Fund: Psoriasis
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Final cost depends on formulary coverage
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
OtezlaView full Otezla profile
SotyktuView full Sotyktu profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.